Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.



from The Medical News http://www.news-medical.net/news/20141231/Final-Phase-1-data-of-zoptarelin-doxorubicin-Phase-12-trial-published-in-Clinical-Cancer-Research.aspx